UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
This study is testing a cell therapy called UC-MSCs for adults with Systemic Lupus Erythematosus (SLE), also known as lupus. Researchers want to see if UC-MSCs can improve kidney function and reduce how active the disease is, while also checking if the treatment is safe and well-tolerated. You could join if you are between 18 and 75 years old and have been diagnosed with SLE based on specific medical criteria. The study will look at how many side effects occur over 168 days to understand the safety of UC-MSCs.
- Study design
- This is an interventional study with a planned enrollment of 10 participants. The phase of the study is not specified.
- What's involved
- Participants will receive a single dose of UC-MSCs, have physical exams, electrocardiograms (ECGs), and fill out surveys. You will also provide blood and urine samples for various lab tests at different visits.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 168 days to monitor for any treatment-emergent adverse events.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Treatment-Emergent Adverse Eventsday 1 to day 168
Analysis for the primary endpoint will be descriptive in nature. safety and tolerability will be measured by the number of AEs and SAEs observed. Adverse event incidents will be summarized descriptively. The severity grade of each recorded AE, and their relationship to study treatment will be analyzed. The action taken and outcome will also be analyzed accordingly.